Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse
Abstract Background The therapeutic effect of poly (ADP-ribose) polymerase inhibitors (PARPi) monotherapy compared with platinum-based chemotherapy, and the impact to subsequent platinum-based chemotherapy after PARPi resistance were inconclusive in breast cancer susceptibility genes (BRCA)1/2-mutat...
Main Authors: | Yana Ma, Jiale Liu, Ning Li, Hualei Bu, Yongwen Huang, Chengjuan Jin, Hao Wen, Shuai Feng, Hui Zhang, Xiaorong Yang, Beihua Kong, Lingying Wu, Kun Song |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-10-01
|
Series: | Journal of Ovarian Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13048-023-01283-2 |
Similar Items
-
Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer
by: María Jesús Rubio Pérez
Published: (2017-05-01) -
Clinical Characteristics, Response to Platinum-Based Chemotherapy and Poly (Adenosine Phosphate-Ribose) Polymerase Inhibitors in Advanced Lung Cancer Patients Harboring BRCA Mutations
by: Johnathan Arnon, et al.
Published: (2023-09-01) -
ATR Inhibitors in Platinum-Resistant Ovarian Cancer
by: Siyu Li, et al.
Published: (2022-11-01) -
Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study
by: Kitagawa Y, et al.
Published: (2019-06-01) -
Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study
by: Mengdi Fu, et al.
Published: (2022-01-01)